Team:Washington/Gram Negative/Build

From 2010.igem.org

(Difference between revisions)
(Recombineering the Type 6 Secretion System)
(Adapting the Type 6 Secretion System Regulation for Use by E. coli)
Line 25: Line 25:
</html>
</html>
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
-
=Adapting the Type 6 Secretion System Regulation for Use by ''E. coli''=
+
 
=Recombineering the Promoter Region of the Type 6 Secretion System=
=Recombineering the Promoter Region of the Type 6 Secretion System=

Revision as of 05:36, 21 October 2010


Recombineering the Promoter Region of the Type 6 Secretion System

Schematic Showing the Engineering of the Fosmid to Contain a Divergent T7 Promoter Instead of the Native Pseudomonas Promoter

Our goal was to replace the native P. aeruginosa regulation of the Type 6 Secretion System with one that can be utilized by the E. coli transcriptional machinery. In order to replace the native promoters with more robust T7 promoters we used a technique called Recombineering to flip out the region containing both promoters and replace it with a gene cassette as follows. We designed primers to create a cassette using PCR, containing the galK galactose metabolism gene flanked by 50 base pairs of homology just outside of the promoter region in the fosmid. The cassette was inserted, giving us a selection factor for our final insertion of our new promoters. A new promoter cassette was designed in total using oligos that encoded the two T7 promoters flanked by the same 50 base pairs of homology used previously, and inserted using recombineering into the fosmid that contained galK in the promoter region.

Creating the Toxin/Antitoxin circuit

Schematic Detailing the Transfer of Tse2 and Tsi2 from P. Aeruginosa into pSB3k3

The Tse2/Tsi2 locus was amplified using PCR. Primers were used that amplified the region from the start codon of Tse2 to the stop codon of Tsi2. The primers were designed to flank the Tse2/Tsi2 product with approximately 40bp regions of homology to the psb3k3-F2620 plasmid. The Tse2/Tsi2 locus was then placed downstream from F2620 via Gibson Cloning. Gibson cloning is a method that joins regions of homology found on the 5' and 3' ends of linearized molecules. The end result of this Gibson cloning reaction is a circularized plasmid containing the final F2620-Tse2/Tsi2 construct in psb3k3. The cicrularized plasmid is then transformed into electrocompetent E. coli Dh5a and the resulting colonies were screened for the insert of expected length via double restriction digest followed by agarose gel electrophoresis. The plasmids that showed inserts of expected length were sequenced, and it was determined that multiple plasmids had the correct F2620-Tse2/Tsi2 inserts.


Designing the Gram(-) Therapeutic       Testing the Gram(-) Therapeutic